Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Ilse Lenaerts"'
Autor:
Deborah Dhuyvetter, Fetene Tekle, Maxim Nazarov, Rob J. Vreeken, Herman Borghys, Frederik Rombouts, Ilse Lenaerts, Astrid Bottelbergs
Publikováno v:
Drug Delivery, Vol 27, Iss 1, Pp 1597-1607 (2020)
The blood–brain barrier (BBB) is often a limiting factor for getting drugs in the brain. Bypassing the BBB by intranasal (IN), or also called nose to brain (NTB), route is an interesting and frequently investigated concept for brain drug delivery.
Externí odkaz:
https://doaj.org/article/3a2c73fb65e34179bd76465154cdf0e3
Autor:
Maarten Ooms, Sofie Celen, Ronald De Hoogt, Ilse Lenaerts, Johnny Liebregts, Greet Vanhoof, Xavier Langlois, Andrey Postnov, Michel Koole, Alfons Verbruggen, Koen Van Laere, Guy Bormans
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 1, Iss 1, Pp 1-17 (2016)
Abstract Background Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. Here, we used [18F]JN
Externí odkaz:
https://doaj.org/article/d4dd4237d5784bcaae606d3049b031e4
Autor:
Herman Borghys, Fetene Tekle, Astrid Bottelbergs, Deborah Dhuyvetter, Rob J. Vreeken, Maxim Nazarov, Ilse Lenaerts, Frederik J. R. Rombouts
Publikováno v:
Drug Delivery
article-version (VoR) Version of Record
Drug Delivery, Vol 27, Iss 1, Pp 1597-1607 (2020)
article-version (VoR) Version of Record
Drug Delivery, Vol 27, Iss 1, Pp 1597-1607 (2020)
The blood–brain barrier (BBB) is often a limiting factor for getting drugs in the brain. Bypassing the BBB by intranasal (IN), or also called nose to brain (NTB), route is an interesting and frequently investigated concept for brain drug delivery.
Autor:
Stephanie Seré, Ilse Lenaerts, Jin Won Seo, Jean-Pierre Locquet, Ulrique Vounckx, Stefaan Van Gool
Publikováno v:
Frontiers in Nanotechnology. 2
Nanomaterials are increasingly valued tools in drug delivery research as they offer enhanced stability, controlled release and more effective drug encapsulation. Though yet to be introduced in clinical trial, mesoporous silica nanoparticles are promi
Publikováno v:
Klinische Pädiatrie.
Autor:
Ineke Fonteyn, Marijke Somers, Greet Vanhoof, Ilse Lenaerts, Koen A. Hens, Xavier Langlois, Peter de Boer, Herman M. R. Hendrickx, Anton Megens
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 349:138-154
The new phosphodiesterase 10A inhibitor (PDE10AI) JNJ-42314415 [3-[6-(2-methoxyethyl)pyridin-3-yl]-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine] was compared with three reference PDE10AIs and eight dopamine 2 (D(2)) receptor blockers. Despite disp
Publikováno v:
Circulation Research; Vol 113
Rationale: In ventricular myocytes of large mammals with low T-tubule density, a significant number of ryanodine receptors (RyRs) are not coupled to the sarcolemma; cardiac remodeling increases noncoupled RyRs. Objective: Our aim was to test the hypo
Autor:
Hassan Rahmoune, Sabine Bahn, Paul C. Guest, Laura W. Harris, Daniel Martins-de-Souza, Nancy Aerts, Ilse Lenaerts, Murtada Alsaif, Bob Amess, Agnes Ernst, Pieter J. Peeters
Publikováno v:
BMC Research Notes, Vol 5, Iss 1, p 146 (2012)
BMC Research Notes
BMC Research Notes
Background: Establishing preclinical models is essential for novel drug discovery in schizophrenia. Most existing models are characterized by abnormalities in behavioral readouts, which are informative, but do not necessarily translate to the symptom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6dc7ec3cdc29714927d7bddeb8caa7f
https://ora.ox.ac.uk/objects/uuid:d8a5e0f4-4f4b-439e-8c73-c0cc894185e8
https://ora.ox.ac.uk/objects/uuid:d8a5e0f4-4f4b-439e-8c73-c0cc894185e8
Autor:
Michel Koole, Ilse Lenaerts, Greet Vanhoof, Johnny Liebregts, Guy Bormans, Alfons Verbruggen, Xavier Langlois, Maarten Ooms, Sofie Celen, Koen Van Laere, Andrey Postnov, Ronald de Hoogt
Publikováno v:
Ejnmmi Radiopharmacy and Chemistry
EJNMMI Radiopharmacy and Chemistry, Vol 1, Iss 1, Pp 1-17 (2016)
EJNMMI Radiopharmacy and Chemistry, Vol 1, Iss 1, Pp 1-17 (2016)
Background Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. Here, we used [18F]JNJ42259152
Autor:
Meri De Angelis, Jesús Alcázar, Greet Vanhoof, Stefanie Dedeurwaerdere, Laura Iturrino, Xavier Langlois, José-Ignacio Andrés, Guy Bormans, Ilse Lenaerts, Sofie Celen
Publikováno v:
Journal of Medicinal Chemistry. 54:5820-5835
We have recently reported the phosphodiesterase 10A (PDE10A) inhibitor 2-[4-[1-(2-[(18)F]fluoroethyl)-4-pyridin-4-yl-1H-pyrazol-3-yl]-phenoxymethyl]-quinoline ([(18)F]1a) as a promising candidate for in vivo imaging using positron emission tomography